Kan He

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11193603/publications.pdf

Version: 2024-02-01

35 papers	3,022 citations	201674 27 h-index	361022 35 g-index
35 all docs	35 docs citations	35 times ranked	2504 citing authors

#	Article	IF	Citations
1	Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3341-3345.	2.2	9
2	Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban. Drug Metabolism and Disposition, 2013, 41, 827-835.	3.3	109
3	Investigating the Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an Intravenous Dose and Use of Drug Transporter Knockout Rats. Drug Metabolism and Disposition, 2013, 41, 906-915.	3.3	49
4	Apixaban inhibition of factor Xa: Microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. Journal of Enzyme Inhibition and Medicinal Chemistry, 2011, 26, 514-526.	5.2	37
5	Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. European Journal of Drug Metabolism and Pharmacokinetics, 2011, 36, 129-139.	1.6	78
6	Tissue Distribution and Elimination of [¹⁴C]Apixaban in Rats. Drug Metabolism and Disposition, 2011, 39, 256-264.	3.3	57
7	Metabolism, pharmacokinetics and pharmacodynamics of the factor Xa inhibitor apixaban in rabbits. Journal of Thrombosis and Thrombolysis, 2010, 29, 70-80.	2.1	15
8	In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies. Drug Metabolism and Disposition, 2010, 38, 448-458.	3.3	219
9	Sulfation of O-Demethyl Apixaban: Enzyme Identification and Species Comparison. Drug Metabolism and Disposition, 2009, 37, 802-808.	3.3	54
10	Highly efficacious factor Xa inhibitors containing Î±-substituted phenylcycloalkyl P4 moieties. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 462-468.	2.2	16
11	Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans. Drug Metabolism and Disposition, 2009, 37, 74-81.	3.3	561
12	Comparative Metabolism of¹⁴C-Labeled Apixaban in Mice, Rats, Rabbits, Dogs, and Humans. Drug Metabolism and Disposition, 2009, 37, 1738-1748.	3.3	99
13	An algorithm for thorough background subtraction from highâ€resolution LC/MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine. Journal of Mass Spectrometry, 2008, 43, 1191-1200.	1.6	70
14	Structureâ€“activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 749-754.	2.2	31
15	Structureâ€“activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moieties. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 2845-2849.	2.2	32
16	Achieving structural diversity using the perpendicular conformation of alpha-substituted phenylcyclopropanes to mimic the bioactive conformation of ortho-substituted biphenyl P4 moieties: Discovery of novel, highly potent inhibitors of Factor Xa. Bioorganic and Medicinal Chemistry Letters, 2008, 18, 4118-4123.	2.2	49
17	Biotransformation of [14C]Dasatinib: In Vitro Studies in Rat, Monkey, and Human and Disposition after Administration to Rats and Monkeys. Drug Metabolism and Disposition, 2008, 36, 1341-1356.	3.3	40
18	Reductive Isoxazole Ring Opening of the Anticoagulant Razaxaban Is the Major Metabolic Clearance Pathway in Rats and Dogs. Drug Metabolism and Disposition, 2008, 36, 303-315.	3.3	48

#	Article	IF	Citations
19	Metabolism and Disposition of Dasatinib after Oral Administration to Humans. Drug Metabolism and Disposition, 2008, 36, 1357-1364.	3.3	170
20	Lacteal Secretion, Fetal and Maternal Tissue Distribution of Dasatinib in Rats. Drug Metabolism and Disposition, 2008, 36, 2564-2570.	3.3	49
21	Troglitazone Thiol Adduct Formation in Human Liver Microsomes: Enzyme Knietics and Reaction Phenotyping. Drug Metabolism Letters, 2008, 2, 184-189.	0.8	2
22	Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa. Journal of Medicinal Chemistry, 2007, 50, 5339-5356.	6.4	387
23	Pyrazole-based factor Xa inhibitors containing N-arylpiperidinyl P4 residues. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1432-1437.	2.2	19
24	Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5041-5048.	2.2	15
25	Design, structureâ€“activity relationship, and pharmacokinetic profile of pyrazole-based indoline factor Xa inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 6481-6488.	2.2	19
26	1-[3-Aminobenzisoxazol-5â€²-yl]-3-trifluoromethyl-6-[2â€²-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1â€²]-biphen-4-yl]-1,4,5,6-tetrahydrop (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 4141-4147.	2.2	58
27	Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5584-5589.	2.2	28
28	Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor.. Blood, 2006, 108, 910-910.	1.4	32
29	METABOLIC ACTIVATION OF TROGLITAZONE: IDENTIFICATION OF A REACTIVE METABOLITE AND MECHANISMS INVOLVED. Drug Metabolism and Disposition, 2004, 32, 639-646.	3.3	115
30	THE CHIMPANZEE (PAN TROGLODYTES) AS A PHARMACOKINETIC MODEL FOR SELECTION OF DRUG CANDIDATES: MODEL CHARACTERIZATION AND APPLICATION. Drug Metabolism and Disposition, 2004, 32, 1359-1369.	3.3	29
31	Bergamottin contribution to the grapefruit juice?felodipine interaction and disposition in humans. Clinical Pharmacology and Therapeutics, 2004, 76, 607-617.	4.7	75
32	Structure-Based Design of Novel Guanidine/Benzamidine Mimics:Â Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants. Journal of Medicinal Chemistry, 2003, 46, 4405-4418.	6.4	85
33	Inactivation of Cytochrome P450 3A4 by Bergamottin, a Component of Grapefruit Juice. Chemical Research in Toxicology, 1998, 11, 252-259.	3.3	307
34	Synthesis and biological evaluation of 6â€²,7â€²-dihydroxybergamottin (6,7-DHB), a naturally occurring inhibitor of cytochrome P450 3A4. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 2593-2598.	2.2	15
35	Identification of the Heme Adduct and an Active Site Peptide Modified during Mechanism-Based Inactivation of Rat Liver Cytochrome P450 2B1 by Secobarbitalâ€. Chemical Research in Toxicology, 1996, 9, 614-622.	3.3	44